Zhao Daijun, Gai Tobe Ruoyan, Cui Min, He Jinchun, Wu Bin
Hongkou CDC, Shanghai, China.
Department of Health Policy, National Center for Child Health and Development, Tokyo, Japan.
Vaccine. 2016 Dec 7;34(50):6158-6165. doi: 10.1016/j.vaccine.2016.11.003. Epub 2016 Nov 9.
To evaluate the cost-effectiveness of adding 23-valent pneumococcal polysaccharide vaccine (PPSV23) to the immunization schedule for the elderly population (age>60years) in Shanghai, China.
A decision-tree model, with data and assumptions adapted from the societal perspective of Shanghai City, was developed to project the health outcomes of PPSV23 vaccination (compared with no vaccination) over a lifetime course. Sensitivity analysis was used to test the model's robustness. The clinical data, utility and treatment costs related to pneumococcal diseases were either cited from the literature or calculated from local sources.
The incremental cost-effectiveness ratio of PPSV23 vaccination compared with no vaccination was $16,699/quality-adjusted life years gained, which was lower than the per capita GDP of Shanghai ($16,840). Sensitivity analyses showed that the model's outcome is robust.
Routine vaccination of the elderly population with PPSV23 is cost-effective in Shanghai, China.
评估在中国上海将23价肺炎球菌多糖疫苗（PPSV23）添加到老年人群（年龄>60岁）免疫规划中的成本效益。
构建了一个决策树模型，数据和假设源自上海市的社会视角，用于预测PPSV23疫苗接种（与未接种相比）在一生过程中的健康结果。采用敏感性分析来检验模型的稳健性。与肺炎球菌疾病相关的临床数据、效用和治疗成本要么引自文献，要么根据当地资料计算得出。
与未接种相比，PPSV23疫苗接种的增量成本效益比为每获得一个质量调整生命年16,699美元，低于上海的人均国内生产总值（16,840美元）。敏感性分析表明该模型的结果具有稳健性。
在中国上海，对老年人群常规接种PPSV23具有成本效益。
